BioPharma Dive - Latest News

Vertex challenger Sionna prices $191M IPO

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations.

Feb 9, 2025 - 22:25
 0
Vertex challenger Sionna prices $191M IPO

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations.

Read More

Tags:

Previous Article

Immune drugmakers Alumis and Acelyrin to merge

Next Article

Bristol Myers, bracing for key patent losses, deepens cost-cutting plan

Related Posts

Character Biosciences raises $93M with an eye on vision loss drugs

Character Biosciences raises $93M with an eye on vision...

Mar 25, 2025  0

J&J keeps forecasts steady as pharma confronts tariff threat

J&J keeps forecasts steady as pharma confronts tariff t...

Apr 15, 2025  0

Novo gains Lexicon obesity drug; CRISPR COO to step down

Novo gains Lexicon obesity drug; CRISPR COO to step down

Mar 28, 2025  0